Anixa Biosciences (ANIX) Cash from Investing Activities (2010 - 2025)
Anixa Biosciences' (ANIX) quarterly Cash from Investing Activities came in at $654000.0 in Q4 2025, down 24.57% YoY from $867000.0 in Q4 2024, and up 178.51% on a QoQ basis from -$833000.0 in Q3 2025.
Anixa Biosciences (ANIX) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Anixa Biosciences (ANIX) has 16 years of Cash from Investing Activities data on file, last reported at $654000.0 in Q4 2025.
- Quarterly Cash from Investing Activities fell 24.57% year-over-year to $654000.0 in Q4 2025, while the trailing twelve-month figure through Oct 2025 was $4.9 million (up 13.8% YoY) and the FY2025 annual result came in at $4.9 million, up 13.8% from the prior year.
- Cash from Investing Activities advanced to $654000.0 in Q4 2025, from -$833000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $2.8 million in Q4 2021 to a low of -$9.9 million in Q4 2022.
- A 5-year average of -$555250.0 and a median of $403000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities sank 3459.61% — and 2025, when it soared 1995.35%.
- Tracing ANIX's Cash from Investing Activities over 5 years: stood at $2.8 million in 2021, then sank by 453.3% to -$9.9 million in 2022, then jumped by 94.02% to -$593000.0 in 2023, then surged by 246.21% to $867000.0 in 2024, then fell by 24.57% to $654000.0 in 2025.
- The last three Cash from Investing Activities figures came in at $654000.0 (Q4 2025), -$833000.0 (Q3 2025), and $2.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | 654,000.00 |
| Oct 31, 2025 | 654,000.00 |
| Jul 31, 2025 | -833,000.00 |
| Jul 31, 2025 | -833,000.00 |
| Apr 30, 2025 | 2.34 Mn |
| Apr 30, 2025 | 2.34 Mn |
| Jan 31, 2025 | 2.70 Mn |
| Jan 31, 2025 | 2.70 Mn |
| Oct 31, 2024 | 867,000.00 |
| Oct 31, 2024 | 867,000.00 |
| Jul 31, 2024 | 2.72 Mn |
| Jul 31, 2024 | 2.72 Mn |
| Apr 30, 2024 | 556,000.00 |
| Apr 30, 2024 | 556,000.00 |
| Jan 31, 2024 | 129,000.00 |
| Jan 31, 2024 | 129,000.00 |
| Oct 31, 2023 | -593,000.00 |
| Oct 31, 2023 | -593,000.00 |
| Jul 31, 2023 | -980,000.00 |
| Jul 31, 2023 | -980,000.00 |